Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2025)

Historic Research & Development for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $7.5 million.

  • Xeris Biopharma Holdings' Research & Development rose 2708.9% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 1366.73%. This contributed to the annual value of $25.6 million for FY2024, which is 1440.85% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Research & Development stood at $7.5 million, which was up 2708.9% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Research & Development registered a high of $10.1 million during Q4 2021, and its lowest value of $3.7 million during Q2 2022.
  • In the last 5 years, Xeris Biopharma Holdings' Research & Development had a median value of $6.0 million in 2022 and averaged $6.2 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Research & Development skyrocketed by 9729.94% in 2021 and then tumbled by 5085.3% in 2022.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Research & Development stood at $10.1 million in 2021, then tumbled by 50.85% to $5.0 million in 2022, then grew by 28.8% to $6.4 million in 2023, then dropped by 4.54% to $6.1 million in 2024, then grew by 22.83% to $7.5 million in 2025.
  • Its Research & Development was $7.5 million in Q3 2025, compared to $8.1 million in Q2 2025 and $7.8 million in Q1 2025.